SNAP Cancer Vaccine Platform

SNAP Cancer Vaccine Platform

A New Approach for
Short Peptide Cancer Vaccines

• SNAP liposomes contain synthetic MPLA, QS-21 and Cobalt porphyrin phospholipid (CoPoP)

• CoPoP enables liposomes to stably bind short MHC-I epitopes upon admixture.

• Better delivery of epitopes and adjuvants to immune cells in draining lymph nodes

•Induce higher frequency of antigen specific CD8+ T cells with > 10,000X lower peptide dosing 

Murine RENCA neoepitope kidney cancer model
Murine RENCA neoepitope kidney cancer model

Effective anti-tumor treatment

•Nanograms of peptide reverse established and metastatic tumor growth in TC-1 tumor model

• Other cancer models show synergy with checkpoint blockade inhibition and other anti-tumor treatments 

Murine TC-1 HPV antigen cancer model
Murine TC-1 HPV antigen cancer model

 

Find the needle in the haystack

 

• SNAP is ideal for multivalent immunization.

• Short peptide microlibraries with SNAP enables finding functional neoepitopes from candidate lists.

• SNAP vaccines are functional even when 59 irrelevant peptides are mixed with a single functional  neoepitope.

 

SNAP finds functional neoepitopes. A single functional one still works when mixed with 59 irrelevant ones
SNAP finds functional neoepitopes. A single functional one still works when mixed with 59 irrelevant ones

 

Make self-antigens immunogenic

 

• Self-antigens typically are poorly immunogenic

• SNAP allows unbiased determination of mutated epitopes with enhanced function using a two-step microlibrary screening method

• Success rate of enhanced epitope selection is ~50%. 10 identified so far against 3 target murine epitopes (Trp-2, AH1, WT1).

Finding an improved Trp2 epitope in murine B16F10 melanoma model
Finding an improved Trp2 epitope in murine B16F10 melanoma model

 

Path for human testing

• CoPoP made by POP BIO produced under GMP at 2.5M dose scale. Other components are obtainable under GMP.

• CoPoP GLP toxicity report available.

• CoPoP is part of EuCorVac-19, tested in a 280 person ph1/2 trial.

•Testing framework for human epitopes

 

SNAP has been clinically validated as part of ongoing Phase I/II clinical studies of the EuCorVac-19 vaccine against COVID-19.

 

Peer reviewed publications

Advanced Science, 2021: Position-Scanning Peptide Libraries as Particle Immunogens for Improving CD8 + T-Cell Responses

ACS Nano, 2021: A Potent Cancer Vaccine Adjuvant System for Particleization of Short, Synthetic CD8 + T Cell Epitopes

Small, 2021: HPV-Associated Tumor Eradication by Vaccination with Synthetic Short Peptides and Particle-Forming Liposomes

JITC, 2021: Immunization with short peptide particles reveals a functional CD8+ T-cell neoepitope in a murine renal carcinoma model

Cancer Immunology Research, 2021: An In Vivo Screen to Identify Short Peptide Mimotopes with Enhanced Anti-Tumor Immunogenicity

Nature Chemistry, 2015: Functionalization of cobalt porphyrin-phospholipid bilayers with his-tagged ligands and antigens

Nature Nanotechnology, 2018: A malaria vaccine adjuvant based on recombinant antigen binding to liposomes

POP BIO is actively seeking partners interested in collaborating with the SNAP technology, reach out to us for more information.